Cybin Partners With Worldwide Clinical Trials


Cybin announced that it has partnered with Worldwide Clinical Trials. Worldwide has a track record of successful patient recruitment for psychedelic trials and global relationships with investigative sites. Worldwide has recent experience managing 11 psychedelic studies in psychiatric populations, including Phase I and Phase II clinical trials conducted in the US, Canada, United Kingdom, and other European countries, across a range of psychedelic compounds and treatment models.

“We are proud to align with Worldwide, a distinguished CRO with a proven track-record of supporting industry-sponsored psychedelic clinical trials," said Doug Drysdale, CEO of Cybin. “Worldwide brings significant regulatory, logistical, and operational expertise as a leader in psychedelic clinical research, making Worldwide the ideal partner for navigating the regulatory landscape surrounding the development of psychedelic-based therapeutics.”

“At Worldwide, we share a passion for Cybin’s mission to revolutionize mental healthcare,” Michael Murphy, MD, PhD, chief medical and scientific officer of Worldwide Clinical Trials. “We are proud to partner with such a diverse and extraordinary group of experts to help create safe and effective psychedelic-based therapies to transform potential treatment options for patients who live with mental health disorders.”


Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder. (2023, July 26). Business Wire.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.